These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10903079)

  • 1. Stage T1 adenocarcinoma of the urinary bladder--complete response after transurethral resection and intravesical bacillus Calmette-Guerin.
    Holmäng S; Aldenborg F
    Scand J Urol Nephrol; 2000 Apr; 34(2):141-3. PubMed ID: 10903079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
    Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
    Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
    Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer.
    Lebret T; Becette V; Hervé JM; Molinié V; Barré P; Lugagne PM; Gentille A; Baglin AC; Botto H
    Eur Urol; 2000 Jun; 37(6):654-9. PubMed ID: 10828663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer.
    Hemdan T; Johansson R; Jahnson S; Hellström P; Tasdemir I; Malmström PU;
    J Urol; 2014 May; 191(5):1244-9. PubMed ID: 24231843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy?
    Dalbagni G; Rechtschaffen T; Herr HW
    J Urol; 1999 Sep; 162(3 Pt 1):708-9. PubMed ID: 10458348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
    Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
    J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
    Brake M; Loertzer H; Horsch R; Keller H
    Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
    Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
    J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
    Kondylis FI; Demirci S; Ladaga L; Kolm P; Schellhammer PF
    J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder.
    Baniel J; Grauss D; Engelstein D; Sella A
    Urology; 1998 Nov; 52(5):785-9. PubMed ID: 9801099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.